![](https://cdn.benzinga.com/files/images/story/2024/08/07/Amgen-stock.jpeg?width=1200&height=800&fit=crop)
Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst
On Tuesday, Amgen Inc. AMGN reported second-quarter sales of $8.39 billion, up 20% year over year and beating the consensus of $8.33 billion. Product sales grew 20%, driven by 26% volume growth, partially offset by a 3% lower net selling price. Excluding …